Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation
Clinical Journal of the American Society of Nephrology · 11.09.2026
DOI: 10.2215/cjn.0000001214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 11.09.2026. Verfasst von Jip Jonker und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Astellas Pharma, Novartis, Astellas Pharma, Novartis.
Abstract (Originalsprache)
Key Points Repeated measurements of plasma tacrolimus concentrations were obtained retrospectively from 295 kidney transplant recipients. Plasma tacrolimus concentration was negatively associated with later eGFR, whereas whole blood concentration was not. Plasma tacrolimus concentration was associated with arteriolar hyalinosis in protocol biopsies, whereas whole blood concentration was not.
Background
Tacrolimus is the cornerstone of immunosuppressive treatment after kidney transplantation. Its application requires therapeutic drug monitoring, which is routinely performed by assessment of whole blood tacrolimus concentrations (WBTC) that largely comprises a pharmacologically inactive fraction. Monitoring tacrolimus exposure using the plasma tacrolimus concentration (PTC) may better reflect the pharmacologic active fraction. We hypothesized that PTC better reflects effectivity and toxicity than WBTC.
Methods
The Amsterdam, LEiden, GROningen trial randomized 295 kidney transplant recipients (KTR) to standard triple immunosuppression, lower tacrolimus exposure, or withdrawal of prednisolone. PTC was measured using liquid chromatography–tandem mass spectrometry. Associations between tacrolimus concentrations and eGFR were analyzed using linear regression, with bootstrap resampling used to compare PTC and WBTC. Associations with biopsy results and rejection were evaluated using logistic regression, and infection risk was assessed with joint modeling.
Results
The mean age was 56.5±13.2 years, and 95 (32%) were female. The mean PTC during the first month post-transplantation (0.31±0.17 ng/ml) was negatively associated with eGFR at 4 weeks (st. β =−0.17 [−0.29 to −0.05], P = 0.006), whereas mean WBTC was not (st. β =0.09 [−0.03 to 0.22], P = 0.15), and the difference between these associations was statistically significant ( P = 0.004). Late mean PTC (6.5–24 months; 0.15±0.07 ng/ml) was negatively associated with eGFR at 2 years (st. β =−0.19 [−0.35 to −0.03], P = 0.02), whereas mean WBTC was not (st. β =0.04 [−0.13 to 0.20], P = 0.66), and this difference was also statistically significant ( P = 0.02). At 2 years, 10 (14%) of the 71 protocol biopsies showed moderate-to-severe arteriolar hyalinosis. Although in a limited number of events, late mean PTC was significantly associated with a risk of arteriolar hyalinosis (odds ratio=1.96 [1.07–3.80], P = 0.03), WBTC was not (odds ratio=1.65 [0.83–3.53], P = 0.17). Neither PTC nor WBTC was significantly associated with a risk of infection in univariable analysis. Twenty-two KTR (7%) experienced biopsy-proven rejection; neither PTC nor WBTC was associated with rejection.
Conclusion
Larger studies are needed to determine whether late PTC is a better marker than WBTC to detect potential tacrolimus-related nephrotoxicity in KTR. Clinical Trial registry name and registration number: NCT01560572.
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands.
- Division of Nephrology, Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
- Division of Nephrology, Department of Internal Medicine, Leiden Transplant Center, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands.
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
ORCID-Profile: Jip Jonker, Joost C van den Born, Marit S van Sandwijk, Armin Gelinck, Soufian Meziyerh, Cornelis Smit, Antonio W Gomes-Neto, Marc Hilhorst, Stefan P Berger, Stephan J L Bakker, Sandrine Florquin, Aiko P J de Vries, Frederike J Bemelman, Daan J Touw, Jan Stephan F Sanders
Förderung
- Astellas Pharma, Novartis
- Astellas Pharma
- Novartis
Zitieren
APA
Jonker, J., van den Born, J. C., Kremer, D., van Sandwijk, M. S., Gelinck, A., Meziyerh, S., Moes, D. J. A. R., Smit, C., Gomes-Neto, A. W., Hilhorst, M., Vart, P., Berger, S. P., Bakker, S. J. L., Florquin, S., de Vries, A. P. J., Bemelman, F. J., Touw, D. J., & Sanders, J. S. F. (2026). Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001214
Vancouver
Jonker J, van den Born JC, Kremer D, van Sandwijk MS, Gelinck A, Meziyerh S, et al. Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001214
BibTeX
@article{Jonker2026,
author = {Jonker, Jip and van den Born, Joost C and Kremer, Daan and van Sandwijk, Marit S and Gelinck, Armin and Meziyerh, Soufian and Moes, Dirk Jan A R and Smit, Cornelis and Gomes-Neto, Antonio W and Hilhorst, Marc and Vart, Priya and Berger, Stefan P and Bakker, Stephan J L and Florquin, Sandrine and de Vries, Aiko P J and Bemelman, Frederike J and Touw, Daan J and Sanders, Jan Stephan F},
title = {Plasma versus Whole Blood Tacrolimus Concentration and Outcomes after Kidney Transplantation},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001214}
}
EUVIMED